Abstract
Anemia is common in chronic kidney disease (CKD). The CHOIR study found increased risk of a composite cardiovascular outcome when anemia was treated with epoetin-alfa to a target hemoglobin level of 13.5 as compared with 11.3 g/dl. Whether this increase applies to all patient subgroups equally is unclear. We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure. © 2010 International Society of Nephrology.
Cite
CITATION STYLE
Fishbane, S., & Miyawaki, N. (2010). Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. Kidney International. Nature Publishing Group. https://doi.org/10.1038/ki.2009.455
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.